European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL. Because no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
Senff
Nancy J
NJ
Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
Noordijk
Evert M
EM
Kim
Youn H
YH
Bagot
Martine
M
Berti
Emilio
E
Cerroni
Lorenzo
L
Dummer
Reinhard
R
Duvic
Madeleine
M
Hoppe
Richard T
RT
Pimpinelli
Nicola
N
Rosen
Steven T
ST
Vermeer
Maarten H
MH
Whittaker
Sean
S
Willemze
Rein
R
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage; D008193:Lyme Disease / Q000150:complications / Q000188:drug therapy; D016393:Lymphoma, B-Cell / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging / Q000379:methods; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins; D000069283:Rituximab; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D000069283:Rituximab